Anti-payload Antibodies
Antibody-drug conjugates (ADCs) are a novel class of anticancer drugs that combine monoclonal antibodies with small molecule toxins, offering high target specificity and cytotoxicity. Following ADC administration, the payload can undergo payload release resulting in an increase in unbound payload and changes in ADC components (i.e., DAR distribution). Therefore, quantitative analysis of the conjugated antibody and payload on the antibody in vivo is crucial for assessing ADC efficacy, evaluating payload exposure at the target site, and determining the significance of DAR distribution and changes in average DAR value for providing overall assessment of ADC stability.
CUSABIO introduces specialized tools for preclinical and clinical stage antibody-drug research - anti-Payload antibodies. These antibodies can be utilized for plasma/serum pharmacokinetic analysis of ADC drugs, determination of drug binding affinity, DAR value analysis, and evaluation of ADC drug efficacy.
CUSABIO currently offers the following types of anti-Payload antibodies.
Analysis Methods for Various Components of ADCs
Comprehensive bioanalytical methods, including ligand binding assays and liquid chromatography-tandem mass spectrometry (LC-MS/MS), are required for the biological analysis of ADCs, covering both large molecule and small molecule analysis. Anti-Payload antibodies play a crucial role in immunogenicity analysis within ADCs and are employed in bridging immunoassays（Bridging LBA） for immunogenicity analysis.
| Analyte Type |
Description |
Typical analytical platforms |
| Total antibody |
Total antibody (conjugated or unconjugated) |
LBA, hybrid LC-MS/MS |
| Total ADC |
Total conjugated antibody (DAR > 1)OR |
LBA |
| Total payload conjugated to antibody (DAR > 1) |
LBA hybrid LC-MS/MS |
| Unconjugated payload |
Payload not conjugated to antibody |
LC-MS/MS |
| Anti-drug antibodies (ADA) |
Antibodies directed against antibody components of ADC, linker, or drug (binding/neutralizing) |
LBA |
Anti payload antibodies for ADC-Anti DXD
Figure. 1 DXD-the most promising payload for next-generation ADCs [1]
Applications
Pharmacokinetic (PK) analysis
Qualitative analysis of ADC DAR values
Preclinical and clinical stage antibody development for drug resistance
Product Advantages
High Purity
Guaranteed above 90% purity verified by SEC-HPLC.
High Specificity
Specificallyrecognizes small molecule toxins.
High Sensitivity
Shows good binding activity verified with approved ADc drugs.
High Affinity
Shows good binding activity verified with approved ADC drugs.
Easy Detection & Cost-Efficient
HRP coniugated anti-DXD mAb available no need with secondary antibody for whole operation.
Tech Team Online
Guaranteed to respond to any questions within 24 hours.
Supplemental Data
High purity verified by SEC-MALS and SDS-PAGE with Anti-DXD antibody
(Code:
CSB-MA996977I2m)
The Mouse Anti-DXD Antibody (Code: CSB-MA996977I2m) has a purity of more than 90% as determined by SEC-MALS and SDS-PAGE.
High purity verified by SEC-MALS and SDS-PAGE with Anti-Eribulin Antibody
(Code:
CSB-MA943989I1m)
The Mouse Anti-DXD Antibody (Code: CSB-MA943989I1m) has a purity of more than 98% as determined by SEC-MALS and SDS-PAGE.
The Binding Activity of Disitamab vedotin (Synonyms: RC48) with Anti-MMAE antibody
(Code:
CSB-MA903890I1m)
Activity: Measured by its binding ability in a functional ELISA. Immobilized Disitamab vedotin (Synonyms: RC48) at 2 μg/mL can bind Anti-MMAE antibody, the EC50 is 11.65 to 15.97 ng/mL.
The Binding Activity of T-DXd(DS-8201) with Anti-DXD antibody
(Code:
CSB-MA996977I2m)
Activity: Measured by its binding ability in a functional ELISA. Immobilized T-DXd(DS-8201) at 2 μg/mL can bind Anti-DXD antibody, the activity was 4-5 times that of other companies.
Customization Services
CUSABIO has developed a range of high-purity, high-sensitivity, and high-affinity anti-Payload antibodies that can be used for preclinical and clinical stage DAR value and PK analysis of ADC drugs. We offer customized anti-Payload antibody services to meet the personalized needs of our customers.
References
[1] Kumar, Seema, ed. An Introduction to Bioanalysis of Biopharmaceuticals. Vol. 57. Springer Nature, 2022.
